Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13794514 | 0.96 | SSTR5 (0.40) | SSTR5KCNH2SCN5ARXFP1F2 | |
| SCHEMBL10074637 | 0.93 | SSTR5 (0.40) | SSTR5KCNH2SCN5AF2TRPV1 | |
| SCHEMBL13794680 | 0.92 | SSTR5 (0.43) | SSTR5RXFP1F2RL3ALDH1A1DYRK1A | |
| SCHEMBL13901014 | 0.89 | SSTR5 (0.38) | SSTR5KCNH2SCN5AF2TRPV1 | |
| SCHEMBL14094055 | 0.88 | SSTR5 (0.38) | SSTR5KCNH2SCN5AF2TRPV1 | |
| SCHEMBL5001501 | 0.86 | SSTR5 (0.41) | SSTR5RXFP1ALDH1A1DYRK1A | |
| SCHEMBL3913134 | 0.86 | SSTR5 (0.42) | SSTR5RXFP1GRIN2BALDH1A1DYRK1A | |
| SCHEMBL10073866 | 0.86 | SSTR5 (0.43) | SSTR5RXFP1ALDH1A1DYRK1AELANE | |
| SCHEMBL10074047 | 0.85 | SSTR5 (0.42) | SSTR5RXFP1ALDH1A1DYRK1A | |
| SCHEMBL14094058 | 0.85 | SSTR5 (0.41) | SSTR5RXFP1GRIN2BALDH1A1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562909-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK SHARP & DOHME (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1663987-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7410992-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410992-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-01-11 | — | — | US | disclosed |
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | REN, KCNH2, KCNH3 | SSTR5 296/4885KCNH2 2/4885SCN5A 55/4885 |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | SSTR5 1031/4885KCNH2 1/4885SCN5A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.